Goldman Sachs: WuXi XDC (02268.HK) commercial production validation becomes a key catalyst for long-term visibility.

Zhito Finance APP has learned that Goldman Sachs issued a research report, giving WuXi XDC (02268.HK) a "Buy" rating, with a target price of HK$97.9, corresponding to a forecast P/E ratio of about 35 times for the next 12 months. The bank pointed out that WuXi XDC has strong momentum in its backlog orders, improved commercialization visibility, and it remains bullish on its multi-year growth prospects, with commercialization catalysts also becoming increasingly clear. The number of process performance qualification (PPQ) projects has reached 21, and the number of Biologics License Application (BLA) submissions is expected to rise.